BioRestorative Therapies, Inc. (BRTX) Stock Analysis & Investment Frameworks
BioRestorative Therapies, Inc. (BRTX) stock analysis on Invetso. Review BioRestorative Therapies, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
BioRestorative Therapies, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
BioRestorative Therapies, Inc. Key Financial Metrics
- Market Cap: $2.08M
- Revenue: $359700.00
- ROE: -423.84%
- ROIC: -464.86%
- Dividend Yield: N/A
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
BioRestorative Therapies, Inc. Investment Frameworks
Invetso analyzes BioRestorative Therapies, Inc. (BRTX) across the following frameworks:
- BioRestorative Therapies, Inc. 10Y Growth Potential
- BioRestorative Therapies, Inc. Scenario Analysis
- BioRestorative Therapies, Inc. Risks & Opportunities
- BioRestorative Therapies, Inc. Economic Moat
- BioRestorative Therapies, Inc. Business Model
- BioRestorative Therapies, Inc. Management
- BioRestorative Therapies, Inc. SWOT Analysis
- BioRestorative Therapies, Inc. Porter's 5 Forces
- BioRestorative Therapies, Inc. PESTLE Analysis
- BioRestorative Therapies, Inc. ESG Analysis